Phcog.Net logo

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Article

    Exercise‑induced anaphylaxis and antileukotriene montelukast

    Sapna Gajbhiye1, Rajendra Prasad Agrawal1, Shubham Atal1, Vikalp Tiwari1, Pradeep Phadnis1 Corresponding author

    1. 1Department of Pharmacology, Mahatma Gandhi Memorial Medical College, Indore, Madhya Pradesh, India.

    CORRESPONDENCE

    Sapna Gajbhiye

    Department of Pharmacology, Mahatma Gandhi Memorial Medical College, Indore, Madhya Pradesh, India.

    drsapnaindore@yahoo.in

    Received: 09-05-2014; Revised: 19-08-2014; Accepted: 17-12-2014.

    Volume 6, Issue 3 · pp. 163–165 · PUBLISHED 2015 · DOI: 10.4103/0976-500X.162007

    View on J Pharmacol. Pharmacother. original site ↗

    ABSTRACT

    We report a rare case of exercise‑induced anaphylaxis (EIA), occurring exclusively with exercise, without any other associated trigger, detected in the prodromal phase, and prevented from additional anaphylaxis episodes by treatment with cetirizine and 10 mg daily of antileukotriene montelukast to date. EIA is a syndrome in which patients experience a spectrum of the symptoms of anaphylaxis ranging from mild cutaneous signs to severe systemic manifestations such as hypotension, syncope, and even death after increased physical activity. Many people have triggers, such as, a variety of foods, various medications, alcohol, cold weather, humidity, and seasonal and hormonal changes along with exercise that cause the symptoms. Typically, either exercise or the specific trigger alone will rarely cause symptoms. It is differentiated from cholinergic urticaria by the absence of response to passive body warming and emotional stress.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Gajbhiye, S., Agrawal, R. P., Atal, S., Tiwari, V., & Phadnis, P. (2015). Exercise‑induced anaphylaxis and antileukotriene montelukast. Journal of Pharmacology and Pharmacotherapeutics, 6(3), 163–165. https://doi.org/10.4103/0976-500X.162007